Pfizer's axitinib favored by FDA panel

9 December 2011

Global drugs behemoth Pfizer (NYSE: PFE) says that the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC) voted unanimously 13 to 0 that data for the investigational oral agent axitinib (proposed trade name Inlyta) support a favorable benefit/risk profile for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of a first-line systemic therapy.

The drug, which was filed for approval in Europe earlier this year (The Pharma Letter June 2), was found to be at least as safe and effective as previously-approved treatments for the disease, such as German drugmaker Bayer and Onyx Pharma’s Nexavar (sorafenib). It also had different side effects than other drugs for the disease, which could be important for patients who cannot tolerate older treatments, said Wyndham Wilson, chairman of the panel and chief of the lymphoma therapeutics section at the National Cancer Institute.

Peak sales of $576 million forecast

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK